İlknur Mansuroğlu

İlknur Mansuroğlu

Auto-generated profile, based on publicly available information

İlknur Mansuroğlu

Department of Pathology, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Turkish Journal of Hematology
Verified
Journal Article
Open access
RERAFET EREN
RAFET EREN
ECEnes Cömert
Enes Cömert
İMİlknur Mansuroğlu
İlknur Mansuroğlu
EDEsma Evrim Doğan
Esma Evrim Doğan
GKGülay Kadıoğlu
Gülay Kadıoğlu

3 September 2022 in Bulletin of the National Research Centre
Verified
Journal Article
Open access
PDF file
EDEsma Evrim Dogan
Esma Evrim Dogan
AAAysenur Arslan
Aysenur Arslan
NDNaciye Demirel
Naciye Demirel
DADemet Aydin
Demet Aydin
IMIlknur Mansuroglu
Ilknur Mansuroglu
GSGuray Saydam
Guray Saydam
Background: Multiple myeloma (MM) is characterized by infiltration of neoplastic plasma cells in the bone marrow. Although many novel agents have been developed in the last decade, MM remains a non-curable disease. The association between bone marrow fibrosis (BMF) and MM survival is unknown, and the considerable changes in patient survival during the last few decades necessitates new studies to examine survival and associated factors in patients with MM. Results: A total of 72 patients with MM, 39 (54.17%) males and 33 (45.83%) females, were included in this retrospective study. Fifteen patients did not have BMF, 55 had BMF (grades 1–4); there were no significant differences between these groups in terms of any of the parameters examined. The 5-year overall survival (OS) rate was 56.5 ± 7.4%. Mean OS was 81.54 ± 7.01 months, mean progression-free survival (PFS) after first-line treatment was 14.07 ± 2.54 months, and mean PFS after autologous stem cell transplantation (ASCT) was 25.92 ± 3.66 months. Survival times or mortality risk were not found to be associated with BMF in any of the analyses (HR 1.208, [95% CI 0.408–3.578], p = 0.733). Mortality risk was increased by 8.163-fold in patients with hypercalcemia (HR 8.163, 95% CI 2.413–27.617, p = 0.001), while it was decreased by 0.243-fold in patients with favourable response to first-line treatment (HR 0.243, 95% CI 0.078–0.756, p = 0.015). Younger patients (< 60 years) had a 1.981-fold greater risk of progression after first-line treatment (HR 1.981, 95% CI 1.111–3.532, p = 0.021), while those with hypercalcemia had a 3.160-fold greater risk of progression after ASCT (HR 3.160, 95% CI 1.103–9.052, p = 0.032). Low haemoglobin levels were also associated with increased mortality risk (p = 0.024). Conclusion: Although hypercalcemia, unfavourable treatment response, young age and a low haemoglobin level were found to be indicators of poor prognosis in patients with MM, no relationship was found between BMF and survival.

1 January 2022 in European Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
BEBerrin Erok
Berrin Erok
İMİlknur Mansuroğlu
İlknur Mansuroğlu
TKTaha Oğuz Keklikoğlu
Taha Oğuz Keklikoğlu
HÖHakan Önder
Hakan Önder

29 September 2022 in European Archives of Medical Research
Verified
Journal Article
Closed access
BEBerrin Erok
Berrin Erok
TKTaha Oğuz Keklikoğlu
Taha Oğuz Keklikoğlu
SÖSuzan Deniz Önol
Suzan Deniz Önol
DADeniz Alagöz
Deniz Alagöz
İMİlknur Mansuroğlu
İlknur Mansuroğlu
HÖHakan Önder
Hakan Önder

17 December 2021 in Medical Journal of Bakırkoy
Verified
Journal Article
Closed access
EDEsma Evrim Doğan
Esma Evrim Doğan
NDNaciye Demirel
Naciye Demirel
EEEsra Turan Erkek
Esra Turan Erkek
DADemet Aydın
Demet Aydın
İMİlknur Mansuroğlu
İlknur Mansuroğlu
RERAFET EREN
RAFET EREN

1 December 2021 in European Archives of Medical Research
Verified
Journal Article
Closed access
BEBerrin Erok
Berrin Erok
EKEyüp Kaya
Eyüp Kaya
TKTanju Kisbet
Tanju Kisbet
NKNaciye Kıs
Naciye Kıs
İMİlknur Mansuroğlu
İlknur Mansuroğlu
HÖHakan Önder
Hakan Önder